IINN Customer Relationships: Early Commercial Rollout via Distributors and Strategic Hospital Evaluations

Inspira Technologies Oxy BHN Ltd (IINN) builds and sells the FDA‑cleared INSPIRA ART100 respiratory support system, monetizing through device sales to hospitals and through third‑party distributors that place and support units in clinical settings. The company’s near‑term revenue profile is driven by selective distributor partnerships and individual hospital procurements rather than broad institutional contracts, making commercial execution and a small number of go‑to partners the critical levers for value creation. Learn more about the issuer and relationship signals at https://nullexposure.com/.

How Inspira is trying to turn product into revenue

Inspira’s operating model is early stage and channel‑dependent: the ART100 is being delivered in pilot and initial commercial shipments while marketing through partners such as Glo‑Med for U.S. distribution and through direct procurement approvals in Israel. Financials show the company is still microscopic by revenue (Revenue TTM $289k) with negative EBITDA and thin gross profit, which underscores that commercial traction rather than product development is the immediate value inflection for investors. The company’s modest institutional ownership (≈7%) and small market capitalization (~$26.1M) reinforce the profile of a nascent medical‑device commercializer.

The practical implications for investors and operators

• Contracting posture: Distributor agreements plus hospital procurement approvals suggest a mixed channel model—Inspira must manage upstream manufacturing and downstream distributor relationships while supporting clinical evaluations.
• Customer concentration and criticality: A small number of named partners and hospital pilots means concentration risk is high, but each relationship is strategically important because the product addresses acute respiratory care.
• Commercial maturity: Evidence of first deliveries and conference exhibits indicates transition from R&D to pilot commercial activities, but scale is not yet present given FY2025–FY2026 reports and TTM revenue.
• Financial sensitivity: With negative operating margins and limited sales, the business is sensitive to single large procurements or a distributor rollout succeeding in a regional market.

If you want continuous tracking of these customer signals, visit https://nullexposure.com/ for more structured coverage.

Named customer and channel relationships described (every item reported)

Glo‑Med Networks Inc.

In January 2025 Inspira delivered FDA‑cleared INSPIRA ART100 systems to Glo‑Med Networks Inc. for distribution across the U.S. East Coast, including placement in a high‑tier New York cardiothoracic surgery division, demonstrating an initial channel rollout strategy (PR Newswire, full‑year 2024 financial results published FY2025).

Glo‑Med Networks

Intellectia reported in FY2026 that Inspira delivered INSPIRA ART100 systems to Glo‑Med for deployment at a leading U.S. hospital, signaling active operational support of end users by Glo‑Med as a commercial partner (Intellectia.ai, news report FY2026).

Glo‑Med Networks Inc. (conference exhibit)

Inspira is featuring its ART100 at AmSECT 2026 at the exhibition booth of its U.S. distributor, Glo‑Med Networks, indicating a joint go‑to‑market presence at a targeted clinical conference to accelerate market adoption (ManilaTimes / GlobeNewswire, February–March 2026 coverage).

Clalit Health Services

Clalit Health Services, Israel’s largest health‑services provider, approved procurement of the ART100 platform, representing a meaningful domestic commercial milestone and an institutional buyer endorsement that can validate clinical utility for other purchasers (Intellectia.ai reporting FY2026; additional newsfilter coverage Feb 2026).

Clalit

A separate newsfeed item recorded in FY2026 similarly notes Inspira secured Clalit approval for the ART100 system (Newsfilter/Intellectia summary, Feb 9 2026), reinforcing that the same institutional procurement was captured across multiple press outlets and news aggregators.

Westchester Medical Center

Inspira has partnered with Westchester Medical Center to evaluate the ART100 in clinical scenarios, a strategic clinical collaboration intended to validate device functionality in real‑world acute respiratory care settings (Intellectia.ai coverage, FY2026).

Westchester Memorial Center

Earlier reporting states the company deployed an ART100 system to Westchester Memorial Center, NY, for clinical evaluation by the hospital’s medical experts as part of the collaboration, confirming an on‑site evaluation was executed (PR Newswire, FY2025 release).

What these relationships collectively signal

The commercial playbook is clear: launch via a distributor in the U.S. while securing institutional procurement and clinical evaluations at select hospitals and large health systems at home in Israel. That pattern produces a mix of benefits and risks:

• Benefit: Distributor placements and conference exhibits accelerate clinician exposure and can generate order funnels without the company building a full U.S. salesforce.
• Risk: High customer concentration and limited revenue so far mean single‑partner execution failures or slow hospital adoption will materially affect near‑term results.
• Execution requirement: Successful conversion from pilot evaluations to recurring purchases and service contracts is essential to move revenue off a laboratory/pilot footing into scaling.

No explicit contractual constraints were provided in the relationship payload, so these characteristics are presented as company‑level signals drawn from the public press and the company’s FY2025–FY2026 communications.

Investment checklist — what to watch next

• Announcements of expanded distribution agreements beyond Glo‑Med or multi‑region distribution rights.
• Transition of pilot evaluations at Westchester and Clalit into repeatable purchase orders or service agreements.
• Quarterly revenue growth and gross margin expansion; current trailing revenue is $289k and gross profit is reported at $2k TTM.
• Cash runway and capital raises given negative EBITDA of ~$12.5M and the need to fund commercialization.

For ongoing monitoring of customer events and follow‑on commercial disclosures, see https://nullexposure.com/.

Bottom line for investors

Inspira is at the commercialization inflection, not yet at scale. The company’s strategy—U.S. distribution via Glo‑Med and targeted institutional approvals and clinical evaluations—creates a pathway to revenue but leaves the company exposed to relationship concentration and execution risk. Investors should prioritize near‑term evidence of order conversion and broader distributor rollouts when assessing upside versus the company’s current valuation and limited revenue base.

To track these customer signals and other issuer relationships on an ongoing basis, visit https://nullexposure.com/ for focused coverage and alerts.